Nabaxor (Rivaroxaban)

Rivaroxaban works by selectively inhibiting coagulation factor Xa, a pivotal enzyme in the cascade that converts prothrombin to thrombin. By blocking factor Xa, the drug reduces thrombin generation, limits fibrin clot formation, and thereby prevents the development and propagation of pathological blood clots while preserving normal clotting mechanisms.

The appropriate dose of Nabaxor is determined by the prescribing clinician based on the specific indication, patient characteristics, renal function, and other clinical factors. Dosage regimens are individualized and should follow the latest prescribing information and local regulatory guidance.

The safety of rivaroxaban during pregnancy and lactation has not been established. It is generally classified as contraindicated in pregnant women unless the potential maternal benefit justifies the potential fetal risk. Breastfeeding mothers should consult their healthcare provider, as the drug may be excreted in breast milk.

To place an order, submit an enquiry on the Nabaxor product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements if applicable), and assistance with import documentation.

Compared with warfarin, a vitamin K antagonist, rivaroxaban offers fixed dosing without routine coagulation monitoring and fewer dietary restrictions. Unlike apixaban, another direct factor Xa inhibitor, rivaroxaban has a once‑daily regimen for many indications, though both share similar efficacy and safety profiles. Choice of therapy depends on patient‑specific factors and clinician judgment.

Nabaxor tablets should be stored at ambient temperature, preferably below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and avoid storing in bathrooms or other humid environments.

Nabaxor is taken orally as a tablet, swallowed whole with water. It may be taken with or without food, according to the prescribing information. Patients should follow the exact timing and dosing instructions provided by their healthcare professional.

The most serious risks include major bleeding events such as intracranial hemorrhage, gastrointestinal bleeding, and spinal or epidural hematoma, especially in patients undergoing neuraxial anesthesia. Other critical concerns are severe allergic reactions and liver injury. Prompt medical attention is required if any signs of serious bleeding or hypersensitivity occur.

Nabaxor is contraindicated in individuals with active pathological bleeding, severe hepatic impairment, or a known hypersensitivity to rivaroxaban or any of its excipients. Caution is also advised for patients with uncontrolled hypertension, recent major surgery, or those receiving other anticoagulants without appropriate monitoring.